Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2023 Earnings Call Transcript

Jennifer Simpson: Good. Thank you. So, we anticipate a total enrollment of approximately 600 patients. And we believe that the enrollment will take in total, roughly 36 months. So, we – the enrollment, I will say, has been quite robust. So, we have been very pleased. And this puts us on track for the interim analysis as early as the early portion of 2024. And so I think that that’s really the first and most important milestone really from an efficacy standpoint, and obviously, we are very pleased to pass the first DSMB pre-specified analysis as well.

Unidentified Analyst: Perfect. Thank you so much.

Jennifer Simpson: Thank you very much.

Operator: Thank you. And there were no other questions in the Q&A queue at this time. That does conclude today’s call. Ladies and gentlemen, thank you for your participation. You may disconnect your lines at this time.